Key Proteo, Inc. — SEC Form D Filing

Key Proteo, Inc. filed an SEC Form D on October 22, 2026, reporting $2.33M raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
October 22, 2026
Amount reported
$2.33M
Round stage
Seed
Industry
Biotechnology
Website
https://www.keyproteo.com

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Many treatable rare genetic disorders do not present symptoms until later in childhood or adulthood, leading to prolonged diagnostic delays and potentially irreversible or fatal complications when left undetected.

Solution

Key Proteo develops the Immuno-SRM proteomics platform and screening test kits that pair mass spectrometry with novel panels to quantify extremely low-abundance protein biomarkers, enabling early detection of rare genetic disorders in newborns.

Why now

Rapid growth in targeted gene and enzyme therapies for rare childhood disorders has created an urgent clinical need for high-sensitivity diagnostic assays capable of detecting diseases before symptom onset.

Verdict

Investors backed this round as a piggyback play on the rare disease therapeutics boom, betting that high-cost gene therapies will force clinical labs to adopt ultra-sensitive protein assays before symptoms emerge. This cleared because high-value therapies create external demand for pre-symptomatic identification, not because state newborn screening labs are eager to replace their entrenched mass spectrometry workflows. Durability remains capped by the notoriously slow, price-sensitive state screening procurement infrastructure and the looming long-term risk of whole-genome sequencing bypassing targeted proteomics entirely.

Source: SEC EDGAR Form D filing